Partial inhibition of aldose reductase by nitazoxanide and its molecular basis.
A little is more than enough: Aldose reductase (AR) is a potential target in a wide range of diseases but its utility may be limited by the side effects caused by complete inhibition. Furthermore, known inhibitors of AR have suffered in clinical evaluation due to poor bioavailability. Here, the clinically used antiprotozoal drug nitazoxanide with proven bioavailability has been shown to partially inhibit AR, potentially circumventing the negatives effects of complete enzyme inhibition.
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006 (China).
Xuehua
X
Zheng
Liping
L
Zhang
Weijia
W
Chen
Yunyun
Y
Chen
Wei
W
Xie
Xiaopeng
X
Hu
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000977:Antiparasitic Agents / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D009574:Nitro Compounds; D013844:Thiazoles / Q000737:chemistry* / Q000494:pharmacology*
D000977:Antiparasitic Agents; D009574:Nitro Compounds; D013844:Thiazoles; D000449:Aldehyde Reductase; C041747:nitazoxanide